View in EDS

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Saved in:
Bibliographic Details
Title: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Authors: Weller, Michael1 michael.weller@usz.ch, Butowski, Nicholas2, Tran, David D3, Recht, Lawrence D4, Lim, Michael5, Hirte, Hal6, Ashby, Lynn7, Mechtler, Laszlo8, Goldlust, Samuel A9, Iwamoto, Fabio10, Drappatz, Jan11, O'Rourke, Donald M12, Wong, Mark13, Hamilton, Mark G14, Finocchiaro, Gaetano15, Perry, James16, Wick, Wolfgang17, Green, Jennifer18, He, Yi18, Turner, Christopher D18
Source: Lancet Oncology. Oct2017, Vol. 18 Issue 10, p1373-1385. 13p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(17)30517-X